EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Natural products‐based antiangiogenic agents: New frontiers in cancer therapy

Tiago Azevedo, Tiago Ferreira, Sheila I. Peña‐Corona, Hernán Cortes, Rita Silva‐Reis, Rui M. Gil da Costa, Ana I. Faustino‐Rocha, Paula A. Oliveira, Daniela Calina, Susana M. Cardoso, Dietrich Büsselberg, Gerardo Leyva‐Gómez und 2 weitere

Food Frontiers · 2024-11 · 5 (6) · 2423-2466

DOI: 10.1002/fft2.466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Food Frontiers, 2024-09. Verfasst von Tiago Azevedo und 13 weiteren Autor:innen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 356 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiogenesis, vital for tumor growth and metastasis, is a promising target in cancer therapy. Natural compounds offer potential as antiangiogenic agents with reduced toxicity. This review provides a comprehensive overview of natural product‐based antiangiogenic therapies, focusing on molecular mechanisms and therapeutic potential. A systematic search identified relevant articles from 2019 to 2023. Various natural compounds, including polyphenols, terpenes, alkaloids, cannabinoids, omega‐3 fatty acids, polysaccharides, proteins, and carotenoids, were investigated for their antiangiogenic properties. Challenges such as dose standardization, routes of administration, and potential side effects remain. Further studies, including in‐depth animal models and human epidemiological studies, must elucidate clinical efficacy and safety. Synergistic effects with current antiangiogenic therapies, such as bevacizumab and tyrosine kinase inhibitors, should be explored. Additionally, the potential hormone‐dependent effects of compounds like genistein highlight the need for safety evaluation. In conclusion, natural products hold promise as adjunctive therapies to conventional antineoplastic drugs in modulating angiogenesis in cancer. However, robust clinical trials are needed to validate preclinical findings and ensure safety and efficacy.

Zitieren

APA

Azevedo, T., Ferreira, T., Peña‐Corona, S. I., Cortes, H., Silva‐Reis, R., Costa, R. M. G. D., Faustino‐Rocha, A. I., Oliveira, P. A., Calina, D., Cardoso, S. M., Büsselberg, D., Leyva‐Gómez, G., Sharifi‐Rad, J., & Cho, W. C. (2024). Natural products‐based antiangiogenic agents: New frontiers in cancer therapy. Food Frontiers, 5(6), 2423-2466. https://doi.org/10.1002/fft2.466

Vancouver

Azevedo T, Ferreira T, Peña‐Corona SI, Cortes H, Silva‐Reis R, Costa RMGD, et al. Natural products‐based antiangiogenic agents: New frontiers in cancer therapy. Food Frontiers. 2024;5(6):2423-2466. doi:10.1002/fft2.466

BibTeX
@article{Azevedo2024,
  author = {Azevedo, Tiago and Ferreira, Tiago and Peña‐Corona, Sheila I. and Cortes, Hernán and Silva‐Reis, Rita and Costa, Rui M. Gil da and Faustino‐Rocha, Ana I. and Oliveira, Paula A. and Calina, Daniela and Cardoso, Susana M. and Büsselberg, Dietrich and Leyva‐Gómez, Gerardo and Sharifi‐Rad, Javad and Cho, William C.},
  title = {Natural products‐based antiangiogenic agents: New frontiers in cancer therapy},
  journal = {Food Frontiers},
  year = {2024},
  volume = {5},
  number = {6},
  pages = {2423--2466},
  doi = {10.1002/fft2.466}
}
Kostenlos starten →